Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography.
benign breast disease
breast neoplasms
longitudinal studies
mass screening
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
24 02 2022
24 02 2022
Historique:
received:
25
11
2021
revised:
11
02
2022
accepted:
18
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Assessing the long-term risk of breast cancer after diagnosis of benign breast disease by mammography is of utmost importance to design personalised screening strategies. We analysed individual-level data from 778,306 women aged 50-69 years with at least one mammographic screening participation in any of ten breast cancer screening centers in Spain from 1996 to 2015, and followed-up until 2017. We used Poisson regression to compare the rates of incident breast cancer among women with and without benign breast disease. During a median follow-up of 7.6 years, 11,708 (1.5%) women had an incident of breast cancer and 17,827 (2.3%) had a benign breast disease. The risk of breast cancer was 1.77 times higher among women with benign breast disease than among those without (95% CI: 1.61 to 1.95). The relative risk increased to 1.99 among women followed for less than four years, and remained elevated for two decades, with relative risk 1.96 (95% CI: 1.32 to 2.92) for those followed from 12 to 20 years. Benign breast disease is a long-term risk factor for breast cancer. Women with benign breast disease could benefit from closer surveillance and personalized screening strategies.
Identifiants
pubmed: 35270331
pii: ijerph19052625
doi: 10.3390/ijerph19052625
pmc: PMC8909630
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 1994 Jul 7;331(1):10-5
pubmed: 8202095
Cancer Causes Control. 2010 Jun;21(6):821-8
pubmed: 20084540
PLoS One. 2021 Mar 23;16(3):e0248930
pubmed: 33755692
Ann Oncol. 2008 Apr;19(4):614-22
pubmed: 18024988
Eur Radiol. 2021 Jul;31(7):4839-4847
pubmed: 33409776
Eur J Obstet Gynecol Reprod Biol. 2016 May;200:16-23
pubmed: 26967341
Ann Surg Oncol. 2018 Oct;25(10):2795-2800
pubmed: 29968026
Breast Cancer Res. 2015 Dec 01;17(1):147
pubmed: 26627479
Radiology. 2013 Mar;266(3):752-8
pubmed: 23249570
J Clin Oncol. 2015 Oct 1;33(28):3137-43
pubmed: 26282663
Ann Intern Med. 2011 Jul 5;155(1):10-20
pubmed: 21727289
J Natl Cancer Inst. 2013 Jul 17;105(14):1043-9
pubmed: 23744877
J Natl Cancer Inst. 2004 Apr 21;96(8):616-20
pubmed: 15100339
Ann Intern Med. 2020 Jan 7;172(1):46-56
pubmed: 31766052
Stat Med. 2004 Apr 15;23(7):1111-30
pubmed: 15057881
Radiology. 2011 Feb;258(2):388-95
pubmed: 21273520
PLoS One. 2014 Feb 03;9(2):e86858
pubmed: 24498285
Br J Cancer. 2019 Jul;121(1):76-85
pubmed: 31114019
Ann Oncol. 2010 May;21 Suppl 3:iii43-51
pubmed: 20427360
Eur J Epidemiol. 2007;22(7):447-55
pubmed: 17594526
N Engl J Med. 2005 Jul 21;353(3):229-37
pubmed: 16034008
Breast Cancer Res Treat. 2015 Feb;149(3):569-75
pubmed: 25636589
N Engl J Med. 1985 Jan 17;312(3):146-51
pubmed: 3965932
Stat Med. 2007 May 20;26(11):2389-430
pubmed: 17031868
Breast J. 2015 Mar-Apr;21(2):168-74
pubmed: 25669425
Breast Cancer Res Treat. 2015 Jan;149(1):237-44
pubmed: 25503778